

**Day One**  
**Wednesday 25<sup>th</sup> April, 2018**

**08.00 Breakfast & Registration**

**08.30 Chairman's Opening Remarks**

Jeroen van Bergen, Director of Research, Immunetune

**Optimising the Identification and Prediction of Neoantigens**

**08.45 Immunopeptidomics: Accelerating the Development of Personalised Cancer Immunotherapy – How can we Improve Identification and Prioritisation of Neoantigens with MS Based Immunopeptidomics?**

Michal Bassani-Sternberg, Immunopeptidomics Unit, Center of Experimental Therapeutics, Department of Oncology, UNIL/CHUV

**09.15 Advances in the Field of In-silico Methods for the Identification of Neoepitopes**

Morten Nielsen, Professor, Group leader Immunoinformatics and Machine-Learning, Department of Bio and Health Informatics,, The Technical University of Denmark

**09.45 An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens**

Trevor Clancy, Co-Founder & CSO, Oncolmmunity

**10.15 Speed Networking**

Jennifer MacKay, Commercial Director, Hanson Wade

**10.45 Morning Refreshments**

**11.15 Overcoming Neoantigen Prediction Challenges in Clinical Application**

Martin Löwer, Head of Bioinformatics, TRON

**11.45 Panel: Determining Best Practices for Neoantigen Prediction**

Jim Johnston, Executive Director, Inflammation, Amgen

Martin Löwer, Head of Bioinformatics, TRON


Michal Bassani-Sternberg, Immunopeptidomics Unit, Center of Experimental Therapeutics, Department of Oncology, UNIL/CHUV

Nadine Defranoux, Program Manager, Parker Institute for Cancer Immunotherapy


**12.15 From Sample to Neoantigens for Vaccines: Key Challenges and Solutions**

Sean Michael Boyle, Director, Bioinformatics Applications, Personalis

**12.45 Lunch & Networking**



- 13.45 Optimising the Neoantigenic Landscape in Low Mutational Burden Tumours for Optimal T Cells Response**  
Sebastiano Battaglia, Assistant Professor of Oncology, Centre of Immunotherapy, Roswell Park Cancer Centre
- 14.15 Identification and Characterization of Presented Tumour Neo-Epitopes from Metastatic Colon Cancer**  
Eustache Paramithiotis, Vice-President, Discovery, Caprion Biosciences Inc
- 14.45 Sensitive Identification and Functional Profiling of Neoepitopespecific T Cells**  
Alexandre Harari, Professor, CHUV
- 15.15 Afternoon Refreshments & Networking**
- 15.45 Immunogenicity of Neoantigen Cancer Vaccines**  
Hyewon Phee, Senior Scientist & Project Manager, Inflammation, Amgen
- 16.15 Determinants of Immunogenicity of Neoantigens**  
Suchit Jhunhunwala, Scientist, Bioinformatics & Computational Biology, Genentech
- 16.45 Chairman's Closing Remarks**  
Jeroen van Bergen, Director of Research, Immunetune
- 17.00 Close of Day One**



**Day Two**  
**Thursday 26<sup>th</sup> April, 2018**

**08.00 Breakfast & Networking**

**09.00 Chairman's Opening Remarks**  
Mohamed Uduman, Scientist, Agenus

**Advancing Cell & Vaccine-based Therapies**

**09.15 Reinvigorating Cancer Vaccines with Neoantigen Targeting Individualised mRNA-based Vaccines for the Treatment of Cancer**  
Matthias Miller, Senior Project Manager, BioNTech

**09.45 Live-Attenuated Double Deleted Listeria Monocytogenes (pLADD) Immunotherapy Targeting MSS CRC**  
Andrea van Elsas, CSO, Aduro Europe

**10.15 Personalised Onco-Immunotherapy: in vivo and ex vivo Vaccination Trials**  
Toni Weinschenk, Founder & CTO, Immatix Biologics

**10.45 Morning Refreshments & Networking**


**11.15 Fast and Cost-Effective Oral Delivery Technology of Personalized T-Cell Vaccines Based on a Live Attenuated Bacteria Platform**  
Heinz Lubenau, COO, VAXIMM GmbH

**11.45 Panel: Maximizing the Potential of Neoantigen-based Targeting for Cancer Vaccines**  
Pamela Carroll, SVP, Immuno-Oncology, Genocera Biosciences  
Matthias Miller, Senior Project Manager, BioNTech  
Andrea van Elsas, CSO, Aduro Europe  
Toni Weinschenk, Founder & CTO, Immatix Biologics

**Guaranteeing Immunogenicity**

**12.45 A New Source of Highly Immunogenic Neoepitopes for Cancer Vaccines**  
Stephen Johnston, Director, Centre for Innovations in Medicine, Biodesign Institute, Arizona State University

**13.15 Lunch & Networking**



**Overcoming Manufacturing Challenges for Personalised Therapies**

- 14.15 Redirecting Anti-Viral Immunity to Fight Cancer with Tumor Specific Neoantigens**  
Kaïdre Bendjama, Personalized, Vaccination Project, Lead Transgene S.A.
- 14.45 Individualised Cancer Neoantigen Vaccines: How can we Make it a Viable Product?**  
Agnete Fredriksen, CSO, Vaccibody
- 15.15 Afternoon Refreshments & Networking**
- 15.45 Manufacturing and Treatment of Patients with Individualized Neoantigen Therapies**  
Mohamed Uduman, Scientist, Agenus
- 16.15 Panel: Advancing Manufacturing Practices for Personalized Cancer Vaccines**  
Agnete Fredriksen, CSO, Vaccibody  
Matthias Miller, Senior Project Manager, BioNTech  
Heinz Lubenau, COO, VAXIMM GmbH  
Kaïdre Bendjama, Personalized, Vaccination Project, Lead Transgene S.A.
- 17.15 Chairman's Closing Remarks**  
Mohamed Uduman, Scientist, Agenus
- 17.30 Close of Summit**